Understanding ITGB2: A Potential Drug Target (G3689)

Target Name: ITGB2

NCBI ID: G3689

ITGB2

Understanding ITGB2: A Potential Drug Target

ITGB2 (leukocyte cell adhesion molecule CD18) is a protein that plays a crucial role in the regulation of cell adhesion and signaling. It is a member of the immunoglobulin family and is expressed in various tissues, including blood, lymphoid organs, and tissues. ITGB2 has been identified as a potential drug target and has been shown to be involved in a variety of biological processes, including inflammation, cancer, and autoimmune diseases.

CD18 is a transmembrane protein that is involved in cell adhesion and signaling. It is a member of the immunoglobulin family and is expressed in various tissues, including blood, lymphoid organs, and tissues. CD18 plays a crucial role in the regulation of cell adhesion and signaling by interacting with various adhesion molecules, including cadherins, E-cadherins, and immunoglobulin-like cell adhesion molecules (Ig-CAMs).

ITGB2 is a critical regulator of cell adhesion and signaling. It is involved in the regulation of adherens junction formation and the maintenance of tight junctions in epithelial cells. ITGB2 also plays a role in the regulation of cell proliferation and survival by interacting with various signaling pathways, including the T-cell signaling pathway and the A37 signaling pathway.

ITGB2 has been shown to be involved in a variety of biological processes, including inflammation, cancer, and autoimmune diseases. For example, ITGB2 has been shown to be involved in the regulation of inflammation by interacting with various signaling pathways, including the T-cell signaling pathway and the NF-kappa-B signaling pathway. ITGB2 has also been shown to be involved in the regulation of cancer progression by interacting with various signaling pathways, including the PI3K/Akt signaling pathway and the T-cell signaling pathway.

ITGB2 has also been shown to be involved in the regulation of autoimmune diseases by interacting with various signaling pathways, including the NF-kappa-B signaling pathway and the JAK/STAT signaling pathway. For example, ITGB2 has been shown to be involved in the regulation of rheumatoid arthritis (RA) by interacting with various signaling pathways, including the NF-kappa-B signaling pathway and the IL-6 signaling pathway.

Despite the potential role of ITGB2 as a drug target, much research is still needed to fully understand its functions and the mechanisms of its involvement in various biological processes. Further research is needed to determine the full extent of ITGB2's involvement in cell adhesion and signaling and to understand its potential as a drug target.

Conclusion

In conclusion, ITGB2 is a protein that plays a crucial role in the regulation of cell adhesion and signaling. Its functions as a potential drug target and its involvement in various biological processes make it an attractive target for further research. Further research is needed to fully understand its mechanisms of action and to determine its potential as a drug target.

Protein Name: Integrin Subunit Beta 2

Functions: Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin ITGAL/ITGB2 is also a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL (PubMed:29100055). Integrins ITGAM/ITGB2 and ITGAX/ITGB2 are receptors for the iC3b fragment of the third complement component and for fibrinogen. Integrin ITGAX/ITGB2 recognizes the sequence G-P-R in fibrinogen alpha-chain. Integrin ITGAM/ITGB2 recognizes P1 and P2 peptides of fibrinogen gamma chain. Integrin ITGAM/ITGB2 is also a receptor for factor X. Integrin ITGAD/ITGB2 is a receptor for ICAM3 and VCAM1. Contributes to natural killer cell cytotoxicity (PubMed:15356110). Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils (PubMed:11812992, PubMed:28807980). Triggers neutrophil transmigration during lung injury through PTK2B/PYK2-mediated activation (PubMed:18587400). Integrin ITGAL/ITGB2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages (PubMed:23775590). In association with alpha subunit ITGAM/CD11b, required for CD177-PRTN3-mediated activation of TNF primed neutrophils (PubMed:21193407)

The "ITGB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets